Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NASDAQ:RIGL

Rigel Pharmaceuticals Q3 2026 Earnings Date & Estimates

Rigel Pharmaceuticals logo
$51.31 -0.14 (-0.27%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$51.30 -0.02 (-0.03%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rigel Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Rigel Pharmaceuticals in Q3 2026

Rigel Pharmaceuticals is expected to post earnings of $0.9210 per share on revenue of $80.10 million. In the same quarter a year earlier Rigel Pharmaceuticals reported $1.46 per share on revenue of $69.46 million. Rigel Pharmaceuticals last reported on August 4, 2026, posting $0.88 per share and beating the $0.0877 consensus estimate. Rigel Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.9210
Expected Revenue
$80.10 million
Prior-Year EPS
$1.46
Prior-Year Revenue
$69.46 million
Expected EPS Growth
-36.9%
Expected Revenue Growth
+15.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.88 (Beat by +$0.7923)
Last Quarter Revenue
$78.70 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Rigel Pharmaceuticals Q3 2026 Earnings FAQ

Rigel Pharmaceuticals (NASDAQ:RIGL) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Rigel Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Rigel Pharmaceuticals to post earnings of $0.9210 per share for Q3 2026.

The consensus revenue estimate for Rigel Pharmaceuticals is $80.10 million for Q3 2026.

Rigel Pharmaceuticals Earnings Headlines

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
October 29 at 8:05 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2026-financial-results-302922949.html
Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine
October 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4956282-rigel-pharmaceuticals-turning-big-pharmas-castoffs-into-a-growth-engine?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
The government is buying stocks
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
 |  Porter & Company (Ad)
HC Wainwright Reaffirms "Buy" Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141127
Rigel Pharmaceuticals, Inc. Highlights New GAVRETO® (Pralsetinib) Data Across RET Fusion-Positive Cancers At ESMO Congress 2026
October 20, 2026  |  marketscreener.comM
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
October 19, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rigel-highlights-new-gavreto-pralsetinib-data-across-ret-fusion-positive-cancers-in-oral-and-poster-presentations-at-esmo-congress-2026-302912054.html
See More Rigel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rigel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rigel Pharmaceuticals and other key companies, straight to your email.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ:RIGL) (NASDAQ:RIGL) is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel’s primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment. The company also markets Rezlidhia (olutasidenib) in the United States for adults with relapsed or refractory acute myeloid leukemia involving a susceptible IDH1 mutation.

In addition to its marketed products, Rigel maintains a development pipeline targeting hematologic malignancies and immune and inflammatory conditions. The company serves the U.S. market directly and relies on licensing, distribution and commercial partnerships to support access to its products in selected international markets.

View Rigel Pharmaceuticals Profile
Earnings Tools